ArticleCell death & disease2026
Piezo1-mediated autophagy promotes immune-inflammatory responses in ankylosing spondylitis.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechano-immune interactions in musculoskeletal aging: Mechanisms and translational perspectives.Theranostics · 2026Review
- Targeting macrophage-mediated TGF-β/BMP signaling in ankylosing spondylitis: from inflammation to pathological bone formation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
This study aimed to investigate the role of Piezo1 in the immune-inflammatory response during the pathogenesis of ankylosing spondylitis (AS) and its underlying mechanisms. RT-qPCR was used to evaluate the expression levels of Piezo1 and autophagy-related genes in the peripheral blood of AS patients. Correlation analyses were conducted to evaluate associations between Piezo1 expression and clinical characteristics of AS patients. Immunohistochemistry (IHC) and Western blotting were performed to determine the expression of Piezo1 and autophagy-related proteins in the synovium of AS patients. In vitro, the effects of Piezo1 and autophagy on primary monocyte-derived macrophages and fibroblast-like synoviocytes (FLS) from AS patients were investigated using Yoda1 and 3-MA interventions. Modulation of the immune-inflammatory response via the Piezo1-autophagy axis was examined through RT-qPCR, Western blotting, and ELISA. Finally, the role of Piezo1 in immune regulation was further assessed in proteoglycan-induced arthritis (PGIA) model using GsMTx4, a Piezo1 inhibitor. Piezo1 expression was markedly elevated in AS patients compared to healthy controls and showed a positive correlation with disease activity, duration, and autophagy levels. Mechanistically, increased Piezo1 expression induced M1 polarization of monocyte-macrophages, leading to increased autophagy and the upregulation of inflammatory factors. Additionally, Piezo1 enhanced autophagy and IL-6 activation in FLS. In the PGIA model, GsMTx4 inhibited autophagy hyperactivation, significantly reduced the immune-inflammatory response, and exerted a protective effect on spinal bone tissue. Immunofluorescence further confirmed that these effects might be associated with reduced autophagy and inflammatory cytokine expression in macrophages and FLS. These findings highlight the role of Piezo1 in AS pathogenesis, suggesting that Piezo1 may contribute to the immune-inflammatory response in AS through autophagy regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.